🔥Weight Loss & Fat Burning

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.

A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.

A first-in-class oral non-peptide GLP-1 receptor agonist in late-stage clinical development for obesity and type 2 diabetes, offering once-daily dosing without fasting requirements.

An FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification, indicated for HIV-associated lipodystrophy and studied for cognitive benefits and visceral fat reduction.

A long-acting amylin receptor agonist in clinical development for obesity, designed for weekly subcutaneous injection and being studied in combination with semaglutide (CagriSema) for enhanced weight loss.

A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor (GHS-R1a), notable for its potent GH-releasing effects and strong appetite stimulation.

A modified fragment of human growth hormone (amino acids 176-191) that specifically promotes fat metabolism and lipolysis without the growth-promoting or diabetogenic effects of full HGH.

A small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that promotes fat loss by increasing NAD+ levels and cellular energy metabolism, available as an oral compound.

A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's disease, repurposed as a potent weight-loss agent.

An experimental peptidomimetic that targets and destroys blood vessels supplying white adipose tissue, causing rapid fat loss through adipose tissue apoptosis in animal studies.

An oral formulation of semaglutide co-formulated with the absorption enhancer SNAC, enabling GLP-1 receptor agonist therapy via daily tablet rather than weekly injection.

The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.

A synergistic combination of tesamorelin (GHRH analogue) and ipamorelin (selective GHRP) that amplifies growth hormone release through dual-pathway stimulation, widely considered the gold standard GH peptide stack.

A synthetic hexapeptide growth hormone secretagogue considered to offer the best balance of potency and side effect profile among the GHRP family.

A synthetic hexapeptide growth hormone secretagogue that potently stimulates GH release through the ghrelin receptor, with additional cardioprotective properties.

A 36-amino acid neuropeptide abundantly expressed in the brain and sympathetic nervous system that regulates appetite, stress resilience, anxiety, and energy homeostasis.

An anti-inflammatory and anti-allergic compound that inhibits IKKε and TBK1 kinases, showing promise for obesity, type 2 diabetes, and metabolic syndrome through unique energy expenditure mechanisms.

A modified growth hormone-releasing hormone fragment with a short half-life (~30 minutes) that stimulates pulsatile growth hormone release, closely mimicking the body's natural GH secretion pattern.

A long-acting growth hormone-releasing hormone (GHRH) analog with a Drug Affinity Complex that extends its half-life to 6-8 days, producing sustained elevated growth hormone and IGF-1 levels.

A modified version of insulin-like growth factor 1 with an extended half-life, potently promoting muscle growth, hyperplasia, and recovery through direct anabolic signaling.

A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.

FDA-approved melanocortin-4 receptor (MC4R) agonist for rare genetic obesity disorders. Targets the brain's hunger signaling pathway to reduce appetite and increase energy expenditure.

A 29-amino acid peptide hormone produced by pancreatic alpha cells that raises blood glucose, promotes fat breakdown, and is used medically for severe hypoglycemia emergencies and diagnostically for GI imaging.

FDA-approved synthetic analog of amylin, a peptide hormone co-secreted with insulin. Used alongside insulin for diabetes management, it slows gastric emptying, reduces glucagon, and promotes satiety — leading to weight loss.

A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.

A 51-amino acid peptide hormone produced by pancreatic beta cells that regulates blood glucose, promotes nutrient uptake into cells, and is used medically for diabetes and off-label in bodybuilding as a powerful anabolic agent.

A popular clinical combination of two growth hormone secretagogues that work through complementary pathways — GHRH receptor (sermorelin) and ghrelin receptor (ipamorelin) — for synergistic GH release with minimal side effects.

A glycoprotein that inhibits myostatin and activin, removing the body's natural brake on muscle growth and enabling significant increases in lean muscle mass.

A mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, protecting cardiolipin and restoring bioenergetics in aging and disease.

An orally active, non-peptide growth hormone secretagogue that mimics ghrelin to raise GH and IGF-1 levels for up to 24 hours per dose, with notable effects on sleep, appetite, and body composition.

The first 29 amino acids of natural GHRH, previously FDA-approved for pediatric GH deficiency. Now widely used off-label for anti-aging GH optimization as a safer alternative to direct HGH therapy.

A truncated form of IGF-1 missing the first 3 amino acids, resulting in 5-10x greater potency than native IGF-1 due to dramatically reduced binding protein affinity, with rapid and localized anabolic effects.

An endogenous peptide ligand for the APJ receptor involved in cardiovascular regulation, fluid homeostasis, angiogenesis, and energy metabolism, with therapeutic potential for heart failure.

A DPP-4 inhibitor that prevents the enzymatic breakdown of incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin secretion for type 2 diabetes management.

A class of biological agents that block myostatin (GDF-8), the body's primary muscle growth inhibitor, enabling significant increases in muscle mass — the 'holy grail' of muscle-building therapeutics.

A splice variant of IGF-1 produced locally in damaged muscle tissue that activates satellite cells and initiates muscle repair and growth following mechanical stress.

A PEGylated version of Mechano Growth Factor with an extended half-life from minutes to hours, allowing systemic distribution and sustained satellite cell activation for muscle growth and repair.

An experimental oral growth hormone secretagogue peptide designed to stimulate GH release through the ghrelin receptor, offering a potential alternative to injectable GH-releasing peptides.

A family of cardiac hormones that regulate blood pressure, fluid balance, and cardiac function — used clinically for heart failure diagnosis and treatment, and increasingly studied for cardioprotective benefits.